{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:09Z","timestamp":1792068849330,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clon.2026.104339","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:52:28Z","timestamp":1790610748000},"page":"104339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Preliminary results of the STARLORD study: a mono-institutional prospective phase II experience of STereotActic Radiotherapy for LOcally advanced non small cell lung cancer ineligible for concurrent chemoRaDiation"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0390-9511","authenticated-orcid":false,"given":"F.","family":"Cuccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Campione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mortellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8155-4552","authenticated-orcid":false,"given":"V.","family":"Figlia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Spera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8144-0168","authenticated-orcid":false,"given":"S.","family":"D'Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Verderame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3444-9015","authenticated-orcid":false,"given":"F.","family":"Azzarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Failla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Carruba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ferrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clon.2026.104339_bib1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2020.1760094","article-title":"Current radiotherapy techniques in NSCLC: challenges and potential solutions","volume":"20","author":"Giaj-Levra","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"10.1016\/j.clon.2026.104339_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103464","article-title":"Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R","volume":"9","author":"Filippi","year":"2024","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.clon.2026.104339_bib3","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","article-title":"Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial","volume":"17","author":"Garassino","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.clon.2026.104339_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102797","article-title":"Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials","volume":"129","author":"Bortolot","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.clon.2026.104339_bib5","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.3390\/jcm12051833","article-title":"Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review","volume":"12","author":"Montrone","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.clon.2026.104339_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2024.09.1437","article-title":"Accelerated Hypofractionated Radiotherapy for Locally Advanced NSCLC: A Systematic Review From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee","volume":"20","author":"Said","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.clon.2026.104339_bib7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ijrobp.2024.03.030","volume":"120","author":"Zhang","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"25","key":"10.1016\/j.clon.2026.104339_bib8","article-title":"Stereotactic Versus Standard Tumor Irradiation in Unresectable Locally Advanced Non-small Cell Lung Cancer With Durvalumab Maintenance: A Multicenter Study With Propensity Score Matching","volume":"23","author":"Cedoz","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.clon.2026.104339_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.21037\/tcr-2025-1396","article-title":"Modern radiotherapy in inoperable locally advanced non-small cell lung cancer: a review of techniques, dose fractionation, and immuno-synergistic strategies","volume":"15","author":"Zhang","year":"2026","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.clon.2026.104339_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102573","article-title":"Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: A systematic review","volume":"118","author":"Allignet","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.clon.2026.104339_bib11","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s11547-018-0858-7","article-title":"Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experience","volume":"123","author":"Figlia","year":"2018","journal-title":"Radiol Med"},{"issue":"12","key":"10.1016\/j.clon.2026.104339_bib12","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00066-016-1057-x","article-title":"Simultaneous integrated protection : A new concept for high-precision radiation therapy","volume":"192","author":"Brunner","year":"2016","journal-title":"Strahlenther Onkol"},{"issue":"8","key":"10.1016\/j.clon.2026.104339_bib14","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: The report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.clon.2026.104339_bib15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.7785\/tcrt.2012.500425","article-title":"Outcome study of cobalt based stereotactic body radiation therapy for patients with inoperable stage III non-small cell lung cancer","volume":"14","author":"Wang","year":"2015","journal-title":"Technol Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.clon.2026.104339_bib16","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/1759-7714.13105","article-title":"Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer","volume":"10","author":"Cong","year":"2019","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.clon.2026.104339_bib17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13014-019-1317-x","article-title":"Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced nonsmall-cell lung cancer: final results of a prospective phase-II trial with a long-term followup","volume":"14","author":"Parisi","year":"2019","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.clon.2026.104339_bib18","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.ijrobp.2022.10.025","article-title":"STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-Small Cell Lung Cancer Patients Unfit for ConcurrEnt RAdio-Chemotherapy: Early Analysis of the START-NEW-ERA Non-Randomised Phase II Trial","volume":"115","author":"Arcidiacono","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104339_bib19","article-title":"Five-Year Survival and Safety of SAbR in Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer unfit for Concurrent Radio-chemotherapy: Focus on Patterns of Local Recurrence from the START-NEW-ERA non-randomized Phase 2 Trial","author":"Arcidiacono","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.clon.2026.104339_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/COC.0000000000000892","article-title":"Stereotactic Body Radiotherapy and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer: Single Arm Phase 2 Study","volume":"45","author":"Kubicek","year":"2022","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104339_bib21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13014-023-02333-1","article-title":"Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study","volume":"18","author":"Jia","year":"2023","journal-title":"Radiat Oncol"},{"issue":"5","key":"10.1016\/j.clon.2026.104339_bib22","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.ijrobp.2023.06.246","article-title":"Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors","volume":"117","author":"Lindberg","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104339_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110439","article-title":"Stereotactic ablative radiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis","volume":"201","author":"Viani","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2026.104339_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2026.1750519","article-title":"From local control to immune modulation: hypofractionated radiotherapy as a backbone for cancer immunotherapy","volume":"16","author":"Zhuang","year":"2026","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.clon.2026.104339_bib25","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3390\/cancers17091524","article-title":"Chemotherapy-Free Treatment with Radiotherapy and Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer","volume":"17","author":"Ozair","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clon.2026.104339_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.058","article-title":"LBA62 Durvalumab after Radiotherapy (RT) in Patients with Unresectable Stage III NSCLC Ineligible for Chemotherapy (CT): Primary Results from the DUART Study","volume":"34","author":"Filippi","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104339_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2025.102803","article-title":"Geriatric screening tools in older patients undergoing concurrent chemoradiotherapy for locally advanced non-small cell lung cancer","volume":"17","author":"Kim","year":"2026","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104339_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2018.02.023","article-title":"ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer","volume":"127","author":"Nestle","year":"2018","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.clon.2026.104339_bib29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jgo.2019.05.002","article-title":"Prognostic value of two geriatric screening tools in a cohort of older patients with early stage Non-Small Cell Lung Cancer treated with hypofractionated stereotactic radiotherapy","volume":"11","author":"Cuccia","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"10.1016\/j.clon.2026.104339_bib30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.prro.2023.04.014","volume":"13","author":"Heinzerling","year":"2023","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104339_bib31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(24)00573-4","article-title":"Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial","volume":"26","author":"Heinzerling","year":"2025","journal-title":"Lancet Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526003109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526003109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:34:37Z","timestamp":1792067677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526003109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":30,"alternative-id":["S0936655526003109"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104339","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preliminary results of the STARLORD study: a mono-institutional prospective phase II experience of STereotActic Radiotherapy for LOcally advanced non small cell lung cancer ineligible for concurrent chemoRaDiation","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104339"}}